Literature DB >> 6214997

Moxalactam pharmacokinetics in children.

M F Romagnoli, K Flynn, G R Siber, D A Goldmann.   

Abstract

We measured the serum concentrations of moxalactam in 10 children receiving antibiotic prophylaxis for surgery and in 18 children treated for documented or suspected infections. Moxalactam was administered intravenously at a dose of 50 mg/kg every 8 h. After the first dose in 28 patients, mean moxalactam concentrations 5 min, 30 min, 2 h, and 8 h after infusion were 257, 177, 82.2, and 17.5 micrograms/ml, respectively. The mean half-life (T 1/2) was 2.44 h (range: 0.55 to 7.96 h). The mean distribution volume (VD) was 0.30 liters per kg. No significant accumulation was observed with multiple doses. Prophylactic and therapeutic groups had similar serum levels, T 1/2, and VD. The five infants less than 1 year of age had a lower mean 30-min level (P less than 0.01), larger VD (P less than 0.001) and longer T 1/2 (P less than 0.025) than the children older than 1 year. A dose of 50 mg/kg produced 30-min levels in excess of 64 microgram/ml in all patients studied, but 8-h trough levels were below the minimal inhibitory concentrations breakpoint of 17 mg/ml in 32% of patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214997      PMCID: PMC183672          DOI: 10.1128/AAC.22.1.47

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

2.  Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid. Implications for therapy of gram-negative bacillary meningitis.

Authors:  S H Landesman; M L Corrado; C C Cherubin; M Gombert; D Cleri
Journal:  Am J Med       Date:  1980-07       Impact factor: 4.965

3.  Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers.

Authors:  J N Parsons; J M Romano; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

4.  Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.

Authors:  W H Hall; B J Opfer; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

5.  In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.

Authors:  J H Jorgensen; S A Crawford; G A Alexander
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

6.  In vitro activities of cefotaxime and moxalactam (LY127935) against Haemophilus influenzae.

Authors:  J H Jorgensen; S A Crawford; G A Alexander
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

7.  Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria.

Authors:  M V Borobio; J Aznar; R Jimenez; F Garcia; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

8.  Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation.

Authors:  T Yoshida; S Matsuura; M Mayama; Y Kameda; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

9.  Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis.

Authors:  S L Kaplan; E O Mason; H Garcia; S J Kvernland; E M Loiselle; D C Anderson; A A Mintz; R D Feigin
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

10.  Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.

Authors:  U B Schaad; G H McCracken; N Threlkeld; M L Thomas
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

View more
  5 in total

Review 1.  A perspective on new beta-lactam antibiotics in pediatric patients.

Authors:  J D Nelson
Journal:  Bull N Y Acad Med       Date:  1984-05

2.  Pharmacokinetics of moxalactam in elderly subjects.

Authors:  M H Andritz; R P Smith; A L Baltch; P E Griffin; J V Conroy; N Sutphen; M C Hammer
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 3.  Pharmacokinetics of anti-infective agents in paediatric patients.

Authors:  D R Butler; R J Kuhn; M H Chandler
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

Review 4.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

Review 5.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.